Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study

Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study

BackgroundThe application of neoadjuvant immunotherapy in the treatment of esophageal cancer needs further exploration. This study aimed to investigate the safety and effectiveness of tislelizumab, an anti-PD-1 antibody, combined with chemotherapy as neoadjuvant treatment for locally advanced esopha...

Full description

Saved in:
Bibliographic Details
Main Authors: Na Zhou, Yuwei Hua, Yuping Ge, Qiang Wang, Chenyu Wang, Jia He, Luo Zhao, Shuangni Yu, Junfang Yan, Lin Zhao, Li Li, Chunmei Bai
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
esophageal squamous cell carcinoma
perioperative treatment
tislelizumab
immunotherapy
neoadjuvant chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1482005/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1482005/full

Similar Items